Intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents is used widely to treat various retinal diseases, including retinal vein occlusion (RVO), diabetic macular edema (DME), myopic choroidal neovascularization (mCNV), and age-related macular degeneration (AMD). Here, VEGFA is linked to age-related macular degeneration.